EYPT
Price
$9.64
Change
-$0.73 (-7.04%)
Updated
Jun 27 closing price
Capitalization
664.03M
32 days until earnings call
MNMD
Price
$6.55
Change
-$0.19 (-2.82%)
Updated
Jun 27 closing price
Capitalization
495.63M
47 days until earnings call
Interact to see
Advertisement

EYPT vs MNMD

Header iconEYPT vs MNMD Comparison
Open Charts EYPT vs MNMDBanner chart's image
EyePoint Pharmaceuticals
Price$9.64
Change-$0.73 (-7.04%)
Volume$1.83M
Capitalization664.03M
Mind Medicine (MindMed)
Price$6.55
Change-$0.19 (-2.82%)
Volume$2.16M
Capitalization495.63M
EYPT vs MNMD Comparison Chart in %
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. MNMD commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Buy and MNMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (EYPT: $9.65 vs. MNMD: $6.56)
Brand notoriety: EYPT and MNMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 190% vs. MNMD: 142%
Market capitalization -- EYPT: $664.03M vs. MNMD: $495.63M
EYPT [@Biotechnology] is valued at $664.03M. MNMD’s [@Biotechnology] market capitalization is $495.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileMNMD’s FA Score has 1 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • MNMD’s FA Score: 1 green, 4 red.
According to our system of comparison, EYPT is a better buy in the long-term than MNMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 6 TA indicator(s) are bullish while MNMD’s TA Score has 4 bullish TA indicator(s).

  • EYPT’s TA Score: 6 bullish, 4 bearish.
  • MNMD’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than MNMD.

Price Growth

EYPT (@Biotechnology) experienced а +14.61% price change this week, while MNMD (@Biotechnology) price change was -6.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

EYPT is expected to report earnings on Jul 30, 2025.

MNMD is expected to report earnings on Aug 14, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($664M) has a higher market cap than MNMD($496M). EYPT YTD gains are higher at: 29.530 vs. MNMD (-5.747). MNMD has higher annual earnings (EBITDA): -75.18M vs. EYPT (-144.55M). EYPT has more cash in the bank: 318M vs. MNMD (212M). MNMD has less debt than EYPT: MNMD (22M) vs EYPT (24.1M). EYPT has higher revenues than MNMD: EYPT (56M) vs MNMD (0).
EYPTMNMDEYPT / MNMD
Capitalization664M496M134%
EBITDA-144.55M-75.18M192%
Gain YTD29.530-5.747-514%
P/E RatioN/AN/A-
Revenue56M0-
Total Cash318M212M150%
Total Debt24.1M22M110%
FUNDAMENTALS RATINGS
EYPT vs MNMD: Fundamental Ratings
EYPT
MNMD
OUTLOOK RATING
1..100
7763
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
9397
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3559
P/E GROWTH RATING
1..100
17100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (30) in the null industry is in the same range as EYPT (61) in the Pharmaceuticals Major industry. This means that MNMD’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Profit vs Risk Rating (93) in the Pharmaceuticals Major industry is in the same range as MNMD (97) in the null industry. This means that EYPT’s stock grew similarly to MNMD’s over the last 12 months.

MNMD's SMR Rating (96) in the null industry is in the same range as EYPT (97) in the Pharmaceuticals Major industry. This means that MNMD’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as MNMD (59) in the null industry. This means that EYPT’s stock grew similarly to MNMD’s over the last 12 months.

EYPT's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for MNMD (100) in the null industry. This means that EYPT’s stock grew significantly faster than MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTMNMD
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 22 days ago
84%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEMAX38.21N/A
N/A
MFS Emerging Markets Equity A
NILIX15.40N/A
N/A
Neuberger Berman International Sel I
EISDX26.71N/A
N/A
Carillon ClariVest Intl Stock C
GSAEX24.62N/A
N/A
Goldman Sachs China Equity Inv
LAVRX15.25N/A
N/A
Lord Abbett Fundamental Equity R3

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-6.94%
LYRA - EYPT
58%
Loosely correlated
-30.83%
OCUL - EYPT
58%
Loosely correlated
-2.43%
ATHE - EYPT
54%
Loosely correlated
+0.34%
BEAM - EYPT
54%
Loosely correlated
-2.04%
CRSP - EYPT
53%
Loosely correlated
+1.69%
More

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
-2.67%
ATAI - MNMD
54%
Loosely correlated
-2.67%
BEAM - MNMD
50%
Loosely correlated
-2.04%
EYPT - MNMD
50%
Loosely correlated
-6.94%
CRSP - MNMD
49%
Loosely correlated
+1.69%
RXRX - MNMD
49%
Loosely correlated
-6.94%
More